Cargando…

Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy

BACKGROUND: Patients with active cancer have an increased risk of cardiovascular diseases (CVDs) among cancer patients receiving endocrine therapy. However, little research has explored the distribution of CVD comorbidities and cardiovascular risk factors (CVRFs) among postmenopause women with breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xu, Liu, Fei, Hidru, Tesfaldet H., Yang, Xiaolei, Wang, Chengfang, Xia, Yunlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423972/
https://www.ncbi.nlm.nih.gov/pubmed/36046689
http://dx.doi.org/10.1155/2022/5104351
_version_ 1784778135345037312
author Han, Xu
Liu, Fei
Hidru, Tesfaldet H.
Yang, Xiaolei
Wang, Chengfang
Xia, Yunlong
author_facet Han, Xu
Liu, Fei
Hidru, Tesfaldet H.
Yang, Xiaolei
Wang, Chengfang
Xia, Yunlong
author_sort Han, Xu
collection PubMed
description BACKGROUND: Patients with active cancer have an increased risk of cardiovascular diseases (CVDs) among cancer patients receiving endocrine therapy. However, little research has explored the distribution of CVD comorbidities and cardiovascular risk factors (CVRFs) among postmenopause women with breast, endometrial, or ovarian cancer prior to active treatment with endocrine therapy. We aimed to explore the distribution of CVD comorbidities and associated CVRF in patients suffering from breast, endometrial, or ovarian cancer prior to the use of endocrine therapy and to assess whether there was compliance with existing hospital recommendations, particularly on the use of lipid-lowering agents to prevent the development of CVD comorbidities in postmenopause women. METHODS: A total of 10,731 postmenopause women with primary breast, endometrial, or ovarian cancer were enrolled between 30th May 2008 and 31st July 2021 from an electronic health record database at the first affiliated hospital of Dalian Medical University. Dyslipidemia was defined according to 2016 Chinese guidelines for adults. Multivariate logistic regression analysis was used to identify the independent predictors of CVD comorbidities in breast, endometrial, and ovarian cancers separately. RESULTS: Overall, 18.9% of the included women had at least one CVD record before endocrine therapy. The highest prevalence of CVD was identified for hypertension (16.5%), followed by coronary heart disease (4.5%), stroke (2.1%), heart failure (1.2%), and atrial fibrillation (1.1%). The most common CVRF among total cancer patients was dyslipidemia, with a remarkable prevalence of 62.8%, followed by diabetes mellitus (8.6%). Notably, only 11.1% of cancer patients were receiving lipid-lowering agents. CONCLUSION: Cancer patients with potential eligibility for endocrine therapy use had an increased risk for CVD comorbidities. Dyslipidemia was the common CVRF. Compliance with recommendations for preventing and managing these comorbidities requires serious attention.
format Online
Article
Text
id pubmed-9423972
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-94239722022-08-30 Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy Han, Xu Liu, Fei Hidru, Tesfaldet H. Yang, Xiaolei Wang, Chengfang Xia, Yunlong Oxid Med Cell Longev Research Article BACKGROUND: Patients with active cancer have an increased risk of cardiovascular diseases (CVDs) among cancer patients receiving endocrine therapy. However, little research has explored the distribution of CVD comorbidities and cardiovascular risk factors (CVRFs) among postmenopause women with breast, endometrial, or ovarian cancer prior to active treatment with endocrine therapy. We aimed to explore the distribution of CVD comorbidities and associated CVRF in patients suffering from breast, endometrial, or ovarian cancer prior to the use of endocrine therapy and to assess whether there was compliance with existing hospital recommendations, particularly on the use of lipid-lowering agents to prevent the development of CVD comorbidities in postmenopause women. METHODS: A total of 10,731 postmenopause women with primary breast, endometrial, or ovarian cancer were enrolled between 30th May 2008 and 31st July 2021 from an electronic health record database at the first affiliated hospital of Dalian Medical University. Dyslipidemia was defined according to 2016 Chinese guidelines for adults. Multivariate logistic regression analysis was used to identify the independent predictors of CVD comorbidities in breast, endometrial, and ovarian cancers separately. RESULTS: Overall, 18.9% of the included women had at least one CVD record before endocrine therapy. The highest prevalence of CVD was identified for hypertension (16.5%), followed by coronary heart disease (4.5%), stroke (2.1%), heart failure (1.2%), and atrial fibrillation (1.1%). The most common CVRF among total cancer patients was dyslipidemia, with a remarkable prevalence of 62.8%, followed by diabetes mellitus (8.6%). Notably, only 11.1% of cancer patients were receiving lipid-lowering agents. CONCLUSION: Cancer patients with potential eligibility for endocrine therapy use had an increased risk for CVD comorbidities. Dyslipidemia was the common CVRF. Compliance with recommendations for preventing and managing these comorbidities requires serious attention. Hindawi 2022-08-22 /pmc/articles/PMC9423972/ /pubmed/36046689 http://dx.doi.org/10.1155/2022/5104351 Text en Copyright © 2022 Xu Han et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Han, Xu
Liu, Fei
Hidru, Tesfaldet H.
Yang, Xiaolei
Wang, Chengfang
Xia, Yunlong
Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy
title Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy
title_full Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy
title_fullStr Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy
title_full_unstemmed Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy
title_short Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy
title_sort postmenopausal women with breast, endometrial, and ovarian cancers have an increased risk for cardiovascular conditions prior to active endocrine therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423972/
https://www.ncbi.nlm.nih.gov/pubmed/36046689
http://dx.doi.org/10.1155/2022/5104351
work_keys_str_mv AT hanxu postmenopausalwomenwithbreastendometrialandovariancancershaveanincreasedriskforcardiovascularconditionspriortoactiveendocrinetherapy
AT liufei postmenopausalwomenwithbreastendometrialandovariancancershaveanincreasedriskforcardiovascularconditionspriortoactiveendocrinetherapy
AT hidrutesfaldeth postmenopausalwomenwithbreastendometrialandovariancancershaveanincreasedriskforcardiovascularconditionspriortoactiveendocrinetherapy
AT yangxiaolei postmenopausalwomenwithbreastendometrialandovariancancershaveanincreasedriskforcardiovascularconditionspriortoactiveendocrinetherapy
AT wangchengfang postmenopausalwomenwithbreastendometrialandovariancancershaveanincreasedriskforcardiovascularconditionspriortoactiveendocrinetherapy
AT xiayunlong postmenopausalwomenwithbreastendometrialandovariancancershaveanincreasedriskforcardiovascularconditionspriortoactiveendocrinetherapy